Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection

Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection

Authors

  • Vildan Manav Department of Dermatology, University of Health Sciences, İstanbul Training and Research Hospital; Cosmetology, İstanbul University Graduate School of Medicine, İstanbul, Turkey
  • Duygu Erdil Department of Dermatology, University of Health Sciences, İstanbul Training and Research Hospital, İstanbul, Turkey
  • Ayşe Esra Koku Aksu Department of Dermatology, University of Health Sciences, İstanbul Training and Research Hospital, İstanbul, Turkey

Keywords:

Sars-CoV-19, Hair loss, ANA positivity, Trichodynia

Abstract

Introduction: Hair loss is one of the most common disorders after coronavirus disease 2019 (COVID-19) infection. This study aimed to investigate the relationship between COVID-19-related hair loss and antinuclear antibody (ANA) positivity and patterns.

Methods: ANA positivity and patterns were analyzed in 30 female COVID-19 patients with hair loss complaints and compared in terms of the presence of autoimmunity between patients with and without COVID-19 exhibiting hair loss.

Results: ANA positivity and cytoplasmic patterns were detected in 40% of the patients with COVID-19 infection and hair loss. Trichodynia and diffuse hair loss were observed in 63.3% and 53.3%, respectively.

Conclusions: In patients with COVID-19-related hair loss, diffuse hair loss and ANA positivity may be related to the high antibody levels triggered by COVID-19 infection.

References

Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667-673. DOI: 10.1016/j.jiph.2020.03.019. PMID: 32340833. PMCID: PMC7142680.

Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413-414. DOI: 10.1038/s41584-020-0448-7. PMID: 32499548. PMCID: PMC7271827.

Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID-19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292-1293. DOI: 10.1002/jmv.27535. PMID: 34931329.

Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020;33(5):e13549. DOI: 10.1111/dth.13549. PMID: 32390279. PMCID: PMC7273098.

Wollina U, Karadağ AS, Rowland-Payne C, Chiriac A, Lotti T. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020;33(5):e13549. DOI: 10.1111/dth.13549. PMID: 32390279. PMCID: PMC7273098.

Hong JK, Chopra S, Kahn JA, Kim B, Khemichian S. Autoimmune hepatitis triggered by COVID-19. Intern Med J. 2021;51(7):1182-1183. DOI: 10.1111/imj.15420. PMID: 34278694. PMCID: PMC8447478.

Nikiphorou E, Alpizar-Rodriguez D, Gastelum-Strozzi A, Buch M, Peláez-Ballestas I. Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. Rheumatology (Oxford). 2021;60(5):2040-2045. DOI: 10.1093/rheumatology/keaa840. PMID: 33496334. PMCID: PMC7928641.

Walters HM, Mian Z, Thomas L, et al. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease. Rheumatology (Oxford). 2022;61(SI2):SI112-SI119. DOI: 10.1093/rheumatology/keab730. PMID: 34599820.

Vlad A, Serban V, Timar R, et al. Increased Incidence of Type 1 Diabetes during the COVID-19 Pandemic in Romanian Children. Medicina (Kaunas). 2021;57(9):973. DOI: 10.3390/medicina57090973. PMID: 34577896. PMCID: PMC8470921.

Aringer M, Johnson SR. Systemic Lupus Erythematosus Classification and Diagnosis. Rheum Dis Clin North Am. 2021;47(3):501-511. DOI: 10.1016/j.rdc.2021.04.011. PMID: 34215376.

Choi WJ, Kim JE, Kang H. Frequency of antinuclear antibody positivity in patients with pattern hair loss. Ann Dermatol. 2015;27(2):210-212. DOI: 10.5021/ad.2015.27.2.210. PMID: 25834364. PMCID: PMC4377414.

Martínez-Velasco MA, Vázquez-Herrera NE, Maddy AJ, Asz-Sigall D, Tosti A. The Hair Shedding Visual Scale: A Quick Tool to Assess Hair Loss in Women. Dermatol Ther (Heidelb). 2017;7(1):155-165. DOI: 10.1007/s13555-017-0171-8. PMID: 28220468. PMCID: PMC5336434.

Peker BO, Şener AG, Kaptan Aydoğmuş F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J Immunol Methods. 2021;499:113174. DOI: 10.1016/j.jim.2021.113174. PMID: 34737165. PMCID: PMC8556075.

Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280-2282. DOI: 10.1111/ced.15336. PMID: 35867020. PMCID: PMC9349949.

Chang SH, Minn D, Kim YK. Autoantibodies in moderate and critical cases of COVID-19. Clin Transl Sci. 2021;14(5):1625-1626. DOI: 10.1111/cts.13036. PMID: 33934534. PMCID: PMC8239866.

Gazzaruso C, Carlo Stella N, Mariani G, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095-2097. DOI: 10.1007/s10067-020-05180-7. PMID: 32462425. PMCID: PMC7251560.

Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020;3:100073. DOI: 10.1016/j.jtauto.2020.100073. PMID: 33263103. PMCID: PMC7691817.

Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021;14(2):502-508. DOI: 10.1111/cts.12908. PMID: 32989903. PMCID: PMC7536986.

Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. DOI: 10.1111/cts.12953. PMID: 33306235. PMCID: PMC8212749.

Trahtemberg U, Fritzler MJ; On behalf of the COVID-19 chapter of the “Longitudinal Biomarkers in Lung Injury” study group. COVID-19-associated autoimmunity as a feature of acute respiratory failure. Intensive Care Med. 2021;47(7):801-804. DOI: 10.1007/s00134-021-06408-z. PMID: 33928414. PMCID: PMC8084710.

Yorulmaz A, Hayran Y, Ozdemir AK, et al. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. J Cosmet Dermatol. 2022;21(6):2610-2617. DOI: 10.1111/jocd.14413. PMID: 34449961.

Kłosowicz A, Englert K, Pełka K, Pastuszczak M, Pastuszczak A. Autoimmunity in lichen planopilaris patients. Pol Merkur Lekarski. 2019;46(271):32-35. PMID: 30810113.

Chang SE, Feng A, Meng W, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. DOI: 10.1038/s41467-021-25509-3. PMID: 34521836. PMCID: PMC8440763.

Massabki PS, Accetturi C, Nishie IA, da Silva NP, Sato EI, Andrade LE. Clinical implications of autoantibodies in HIV infection. AIDS. 1997;11(15):1845-1850. DOI: 10.1097/00002030-199715000-00009. PMID: 9412703.

Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K, Fritzler MJ. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell. 2002;13(4):1338-1351. DOI: 10.1091/mbc.01-11-0544. PMID: 11950943. PMCID: PMC102273.

Pazini AM, Fleck J, dos Santos RS, Beck ST. Clinical relevance and frequency of cytoplasmic and nuclear dense fine speckled patterns observed in ANA-HEp-2. Rev Bras Reumatol. 2010;50(6):655-660. PMID: 21243306.

Xerfan EMS, Andersen ML, Facina AS, Tufik S, Tomimori J. The role of sleep in telogen effluvium and trichodynia: A commentary in the context of the current pandemic. J Cosmet Dermatol. 2021;20(4):1088-1090. DOI: 10.1111/jocd.13929. PMID: 33387387.

Rebora A. Trichodynia: a review of the literature. Int J Dermatol. 2016;55(4):382-384. DOI: 10.1111/ijd.13204. PMID: 26696219.

Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. J Am Acad Dermatol. 2014;71(3):415.e1-415.e15. DOI: 10.1016/j.jaad.2014.04.070. PMID: 25128118.

Baldari M, Montinari M, Guarrera M, Rebora A. Trichodynia is a distinguishing symptom of telogen effluvium. J Eur Acad Dermatol Venereol. 2009;23(6):733-734. DOI: 10.1111/j.1468-3083.2009.03201.x. PMID: 19281607.

Kivanç-Altunay I, Savaş C, Gökdemir G, Köşlü A, Ayaydin EB. The presence of trichodynia in patients with telogen effluvium and androgenetic alopecia. Int J Dermatol. 2003;42(9):691-693. DOI: 10.1046/j.1365-4362.2003.01847.x. PMID: 12956679.

Durusoy C, Ozenli Y, Adiguzel A, et al. The role of psychological factors and serum zinc, folate and vitamin B12 levels in the aetiology of trichodynia: a case-control study. Clin Exp Dermatol. 2009;34(7):789-792. DOI: 10.1111/j.1365-2230.2008.03165.x. PMID: 19508569.

Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11-18. DOI: 10.1016/j.jdin.2021.07.006. PMID: 34368790. PMCID: PMC8328568.

Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. Exp Dermatol. 2021;30(7):999-1000. DOI: 10.1111/exd.14352. PMID: 33838048. PMCID: PMC8250761.

Downloads

Published

2023-04-29

Issue

Section

Original Article

How to Cite

1.
Antinuclear Antibody Positivity in Patients With Hair Loss After COVID-19 Infection. Dermatol Pract Concept [Internet]. 2023 Apr. 29 [cited 2024 May 19];13(2):e2023081. Available from: https://dpcj.org/index.php/dpc/article/view/2641

Share